Compare · NTRA vs PDCO
NTRA vs PDCO
Side-by-side comparison of Natera Inc. (NTRA) and Patterson Companies Inc. (PDCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and PDCO operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $47.01B, about 17.0x PDCO ($2.76B).
- NTRA has hit the wire 8 times in the past 4 weeks while PDCO has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 7 for PDCO).
- Company
- Natera Inc.
- Patterson Companies Inc.
- Price
- -
- -
- Market cap
- $47.01B
- $2.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 1992
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 7
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Patterson Companies Inc.
Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. It operates through three segments; Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritionals, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.
Latest NTRA
- UBS resumed coverage on Natera with a new price target
- Rothschild & Co Redburn initiated coverage on Natera with a new price target
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $5,917,907 worth of shares (18,160 units at $325.88) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 110,859 units (SEC Form 4) to satisfy withholding tax
- CEO AND PRESIDENT Chapman Steven Leonard sold $545,041 worth of shares (1,698 units at $320.99) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 98,199 units (SEC Form 4)
- New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
- PRESIDENT, CHIEF BUS. OFFICER Fesko John was granted 20,000 shares and sold $2,095,411 worth of shares (6,517 units at $321.53) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 197,257 units (SEC Form 4) (tax liability)
- Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
- Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
Latest PDCO
- SEC Form 15-12G filed by Patterson Companies Inc.
- SEC Form 8-K filed by Patterson Companies Inc.
- Director Tomczik Pamela J returned 7,820 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Schrimsher Neil A returned 48,788 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Mckoy Philip returned 18,114 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Frenzel Robert returned 38,242 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Feragen Jody H returned 56,145 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Buck John D returned 92,869 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Blanco Alex N returned 41,300 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Agarwal Meenu returned 12,788 shares to the company, closing all direct ownership in the company (SEC Form 4)